LncRNA RHPN1-AS1 promotes the progression of nasopharyngeal carcinoma by targeting CELF2 expression.


Journal

Experimental and molecular pathology
ISSN: 1096-0945
Titre abrégé: Exp Mol Pathol
Pays: Netherlands
ID NLM: 0370711

Informations de publication

Date de publication:
10 2021
Historique:
received: 29 04 2021
revised: 23 06 2021
accepted: 01 08 2021
pubmed: 7 8 2021
medline: 24 12 2021
entrez: 6 8 2021
Statut: ppublish

Résumé

This study aims to investigate the role of lncRNA RHPN1-AS1 in NPC and its potential regulatory mechanism. The expression of RHPN1-AS1 in tissues and cells was measured by qRT-PCR. The effect of RHPN1-AS1 silencing on biological functions of NPC cells was detected by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays. The protein expression was measured by western blot. The RBPs of RHPN1-AS1 were predicted by Starbase and LncTar, and verify by RIP assay. ESTIMATE was used to analyze the relationship between CELF2 expression and tumor purity. GSEA was used to analyze the downstream signaling pathway of CELF2. In our study, RHPN1-AS1 was up-regulated in NPC tissues and cells. RHPN1-AS1 silencing inhibited cell viability, capacity of proliferation, migration and invasion, promoted apoptosis, decreased protein expression of Bcl-2, MMP2/9, increased protein expression of Bax, caspase-3, and TIMP2 of NPC cells. CELF2 was a target of RHPN1-AS1 and was down-regulated in NPC tissues and cells. CELF2 level was associated with tumor purity negatively. Low expression of CELF2 activated mTORC1 signaling pathway and increased protein expression of p-mTORC1/mTORC1 and p-P70S6K/P70S6K. RHPN1-AS1 silencing eliminated the activating effect of CELF2 silencing on mTORC1 signaling pathway. Moreover, CELF2 silencing reversed the inhibitory effect of RHPN1-AS1 on NPC progression. In conclusion, our findings indicated that RHPN1-AS1 plays an important role in NPC via activating mTORC1 signaling which is modulated by CELF2. RHPN1-AS1 may serve as a potential therapeutic target for NPC treatment.

Identifiants

pubmed: 34358519
pii: S0014-4800(21)00070-8
doi: 10.1016/j.yexmp.2021.104671
pii:
doi:

Substances chimiques

CELF Proteins 0
CELF2 protein, human 0
Nerve Tissue Proteins 0
RNA, Long Noncoding 0
RNA-Binding Proteins 0
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104671

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Yanxiang Zhao (Y)

Department of Otorhinolaryngology, Weifang Traditional Chinese Medicine Hospital, Weifang, Shandong 261041, PR China.

Haiyan Zhou (H)

Department of Infectious Diseases, Weifang people's Hospital, Weifang, Shandong 261041, PR China.

Wenhui Dong (W)

Department of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, PR China. Electronic address: dwh0702@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH